# Pembrolizumab in Advanced Hepatocellular Carcinoma as Second-line Treatment After Failure of Sorafenib

> **NCT03163992** · PHASE2 · COMPLETED · sponsor: **Samsung Medical Center** · enrollment: 60 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03163992
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-26
- **Primary completion:** 2021-05-17
- **Final completion:** 2021-05-17
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2022-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03163992

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03163992, "Pembrolizumab in Advanced Hepatocellular Carcinoma as Second-line Treatment After Failure of Sorafenib". Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/clinical/NCT03163992. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*